scholarly journals 872. Number of Sexual Partners and Patient-Reported Outcomes among Older Adults Living With HIV

2021 ◽  
Vol 8 (Supplement_1) ◽  
pp. S527-S528
Author(s):  
Peter Mazonson ◽  
Jeff Berko ◽  
Theoren Loo ◽  
Giselle D Coelho ◽  
Erik Lowman ◽  
...  
Keyword(s):  
Sexual Partner ◽  
Clinical Care ◽  
Sexual Partners ◽  
Pairwise Comparisons ◽  
Research Support ◽  
Independent Contractor ◽  
Patient Reported ◽  
Number Of Sexual Partners ◽  
Living With Hiv ◽  
Research Grant

Abstract Background Many older (age 50+) adults living with HIV (OALWH) are sexually active. However, little is known about the relationship between number of sexual partners and mental health outcomes among OALWH. Methods Data were utilized from the Aging with Dignity, Health, Optimism and Community (ADHOC) cohort, an observational study of OALWH from ten US clinics. To measure sexual activity, participants were asked “How many sexual partners have you had in the last year?” with response options ranging from zero to “greater than five.” Loneliness was measured using the Three-item Loneliness Scale, and depression was measured using the Patient Health Questionnaire-2. Significance was determined by Kruskal-Wallis tests followed by unadjusted pairwise comparisons. Results Of 1,027 participants, the mean (SD) age was 58.9 (6.1) and 876 (85%) were male. 312 (30%) had zero sexual partners in the past year, 308 (30%) had one partner, 197 (19%) had 2-5 partners, and 210 (20%) had >5 partners. Of the participants with one partner, 230 (75%) were married, coupled or partnered, and 78 (25%) were single, widowed, separated, or divorced (Single). Figure 1 shows that people with one partner were significantly less lonely than any other group (p< 0.01 for pairwise comparisons), and all other groups were statistically similar to each other. This pattern was also seen with depression (p< 0.01 for pairwise comparisons, Figure 2). Among subgroup of people with one sexual partner, those who were married, coupled or partnered were less lonely (4.41 vs. 5.67, p< 0.01) and less depressed (0.95 vs 1.38, p=0.02) than those who were single, widowed, separated, or divorced. Conclusion Among OALWH, people with one sexual partner were less lonely and depressed than people with zero or with ≥2 partners. Furthermore, people with one sexual partner who were married or in a committed relationship were less lonely and depressed than people with one sexual partner who were not. Disclosures Peter Mazonson, MD, MBA, ViiV Healthcare (Grant/Research Support) Jeff Berko, MPH, BS, ViiV Healthcare (Scientific Research Study Investigator) Theoren Loo, MPH, ViiV Healthcare (Grant/Research Support) Giselle D. Coelho, MD. MPHTM, Lilly (Research Grant or Support)Medscape, Clinical Care Options (Independent Contractor)Viiv, Gilead, Janssen (Advisor or Review Panel member, Research Grant or Support) Erik Lowman, MD, Gilead (Grant/Research Support)Janssen (Grant/Research Support)ViiV (Grant/Research Support) Peter Shalit, MD, PhD, Abbvie (Grant/Research Support)Gilead Sciences (Consultant, Grant/Research Support, Speaker’s Bureau)Glaxo Smithkline (Consultant, Grant/Research Support)Janssen (Consultant, Grant/Research Support, Speaker’s Bureau)Merck (Grant/Research Support, Speaker’s Bureau)Thera (Speaker’s Bureau)ViiV Healthcare (Speaker’s Bureau) Frank Spinelli, MD, ViiV Healthcare (Employee)

scholarly journals 1768. Efficacy and Safety of Switching From Boosted-Protease Inhibitors (bPI) Plus Emtricitabine/Tenofovir Disoproxil Fumarate (F/TDF) Regimens to the Once Daily (QD), Single-Tablet Regimen (STR) of Darunavir/Cobicistat/Emtricitabine/Tenofovir Alafenamide (D/C/F/TAF) in Virologically Suppressed, HIV-1-Infected Adults: Week 96 Results of the Phase 3, Randomized, Non-Inferiority EMERALD Trial

2018 ◽  
Vol 5 (suppl_1) ◽  
pp. S65-S65 ◽  
Author(s):  
Joseph Eron ◽  
Chloe Orkin ◽  
Douglas Cunningham ◽  
Federcio Pulido ◽  
Frank Post ◽  
...  
Keyword(s):  
Extension Phase ◽  
Virologic Suppression ◽  
Efficacy And Safety ◽  
Research Support ◽  
Open Label ◽  
Genetic Barrier ◽  
Independent Contractor ◽  
Grant Recipient ◽  
Hiv 1 ◽  
Research Grant

Abstract Background The QD STR D/C/F/TAF 800/150/200/10 mg was noninferior to bPI + F/TDF at 48 weeks in EMERALD. Efficacy and safety of D/C/F/TAF through week 96 are presented. Methods EMERALD (NCT02269917) is a randomized, active-controlled, open-label, international, multicenter noninferiority trial. Virologically suppressed (VL<50 c/mL for ≥2 months) ART experienced (previous non-DRV VF allowed) HIV-1-infected adults were randomized (2:1) to switch to D/C/F/TAF or continue bPI + F/TDF over 48 weeks. Patients could then continue on D/C/F/TAF or switch from bPI + F/TDF to D/C/F/TAF at week 52 (Late switch, 44 weeks D/C/F/TAF exposure) in a single-arm extension phase until week 96. The percentage of patients with virologic rebound (confirmed VL ≥50 c/mL) cumulative through week 48 and week 96 were primary and secondary endpoints, respectively. Results Of 1141 randomized and treated patients (58% had received ≥5 previous ARVs including screening ARVs; 15% had previous non-DRV VF), 1,080 continued in the extension phase (N = 728 D/C/F/TAF; N = 352 late switch). Few patients had virologic rebound cumulative through week 96 in the D/C/F/TAF arm (3.1%, 24/763). Virologic rebound occurred in 2.3% (8/352) in the late switch arm over 44 weeks D/C/F/TAF treatment. Many rebounders (14/24 and 2/8) resuppressed by week 96. At week 96 a high percentage of patients in the D/C/F/TAF arm (90.7%, 692/763) were suppressed (VL<50 c/mL). In the late switch arm, 93.8% (330/352) maintained virologic suppression after 44 weeks of treatment. No DRV, primary PI, TFV, or FTC RAMs were seen post baseline. Few serious AEs and AE related discontinuations occurred in either arm (Table 1). Improvements in renal and bone parameters were maintained in the D/C/F/TAF arm and seen in the late switch arm (week 52–96), with a small change in TC/HDL-C ratio (Table 1). Conclusion Switching to D/C/F/TAF maintained high virologic suppression rates (>90%) at week 96 with no resistance development, and was well tolerated over 96 weeks with bone, renal, and lipid safety consistent with known TAF and cobicistat profiles. Efficacy and safety results in the late switch arm were consistent with week 48 results in the D/C/F/TAF arm. D/C/F/TAF combines the efficacy and high genetic barrier to resistance of DRV with the safety benefits of TAF, even in patients with a history of non-DRV VF. Disclosures J. Eron Jr., Gilead: Consultant and Grant Investigator, Consulting fee and Research grant. Janssen: Consultant, Consulting fee and Research grant. C. Orkin, AbbVie, Abbott, Boehringer Ingelheim, BMS, Gilead, GSK, Janssen, ViiV: Grant Investigator and Research Contractor, Research grant and Research support. D. Cunningham, Janssen: Investigator, Research grant. Gilead: Investigator, Research grant. F. Pulido, Janssen: Consultant, Investigator and Scientific Advisor, Consulting fee, Research support and Speaker honorarium. F. Post, Gilead: Consultant and Grant Investigator, Consulting fee and Grant recipient. Viiv: Grant Investigator, Grant recipient. Janssen: Consultant, Consulting fee. MSD: Consultant, Consulting fee. S. De Wit, Janssen: Investigator, Research grant. E. Lathouwers, Janssen: Employee and Shareholder, Salary. V. Hufkens, Janssen: Employee and Shareholder, Salary. R. Petrovic, Janssen R&D: Independent Contractor, Consulting fee. E. Van Landuyt, Janssen: Employee and Shareholder, Salary.

scholarly journals First sexual intercourse and high parity are the most influential factors of precancerous cervical lesion

2020 ◽  
Vol 28 (3) ◽  
pp. 113
Author(s):  
Hadi Ashar ◽  
Ina Kusrini ◽  
Arif Musoddaq ◽  
Ika Puspita Asturiningtyas
Keyword(s):  
Sexual Intercourse ◽  
Sexual Partner ◽  
Sexual Partners ◽  
Influential Factors ◽  
High Parity ◽  
First Sexual Intercourse ◽  
A Value ◽  
Number Of Sexual Partners ◽  
Cancerous Lesions ◽  
Menarche Age

Objectives: to analyze the relationship between characteristics, parity and maternal reproductive history with the risk of cervical pre-cancerous lesions.Materials and Methods: Cross Sectional Survey, in 2016 Non-Communicable Disease study, with a population of women aged 25-64 years, living in urban areas. A total of 1,547 samples were selected from the census blocks that were prepared to IVA examination. The variables in this article are maternal characteristics, menarche, age of first sexual intercourse, number of partners, parity and contraceptive use, as independent variables and cervical pre-cancerous lesions as dependent variables.Results: Factors influencing cervical pre-cancerous lesions were: Menarche with a value of P = 0.018; Age of first sexual intercourse with a value of P = 0,000; Number of sexual partners with a value of P = 0.023; and parity with a value of P = 0.049. Multivariate test results show that the age of first time having sex less than 20 years has a 2.3 risk; Mothers with high parity (> 4 children) and having more than one sexual partner have a 16.5 risk.Conclusion: Menarche, age of first sexual intercourse, number of sexual partners and parity affect the incidence of cervical cancerous lesions. The most influential Factors are: the age of first sexual intercourse less than 20 years, and mothers with high parity who have more than one sexual partner.

scholarly journals 1362. Adding Insult to Injury: Association of Stigmatizing Language and Suboptimal Outcomes in People Who Inject Drugs

2021 ◽  
Vol 8 (Supplement_1) ◽  
pp. S767-S768
Author(s):  
Joseph Carpenter ◽  
Jillian S Catalanotti ◽  
Melissa Notis ◽  
Christopher J Brokus ◽  
Timothy P Moran ◽  
...  
Keyword(s):  
Best Practice ◽  
Clinical Care ◽  
Continuum Of Care ◽  
Discharge Summary ◽  
Infectious Complications ◽  
Transitions Of Care ◽  
Opioid Use ◽  
Research Support ◽  
Real World Data ◽  
Research Grant

Abstract Background The National Academy of Medicine has identified stigma surrounding substance use disorders (SUDs) and infectious diseases (ID) as a key barrier to integration of opioid use disorder (OUD) and ID services. Prior literature on stigmatizing language in OUD clinical care focuses on surveys and theoretical scenarios rather than real-world data. As part of a larger study of patients admitted for infectious complications of injection drug use (CHOICE), we sought to determine how inpatient physicians describe persons with OUD, as well as associations of this language with outcomes along the OUD continuum of care. Methods CHOICE is a retrospective review of adults hospitalized with an infectious complication of OUD and IDU at four academic medical centers. Included patients were hospitalized between 1/1/2018-12/31/2018, had ICD9/10 diagnosis codes consistent with OUD and acute bacterial/fungal infection, and chart review verification of active infection associated with OUD. Data was abstracted regarding demographics, inpatient interventions, transitions of care, and outcomes 1 year after admission. Potentially stigmatizing language was identified based on the discharge summary. “Abuse” and “misuse” were considered potentially stigmatizing; “use disorder” was considered best practice. Associations of language and outcomes were analyzed via logistic generalized estimating equations. Results A total of 287 subjects met inclusion criteria; 119 (42%) were female and the median age was 40 years (IQR: 32 – 52). The most common terms used to describe OUD were “abuse” (190, 66%) and “IVDU” (119, 42%). “Use disorder” was noted in only 72 (25%) charts. In a regression analysis, any mention of “use disorder” was associated with not leaving against medical advice (OR 2.48, 95% CI 1.24 – 4.95), a plan for ongoing OUD treatment (OR 5.17, 95% CI 2.05-13.0), and addiction-specific follow up (OR 2.94, 95% CI 2.34-3.68). Conclusion In this multicenter retrospective study, inpatient physicians commonly referred to patients with OUD using stigmatizing language. When NIH-preferred language was used this was associated with improved outcomes along the OUD continuum of care, possibly reflecting increased awareness of best practices for treating patients with OUD. Disclosures Ellen Eaton, MD , Gilead (Grant/Research Support) Ellen Eaton, MD , Gilead (Individual(s) Involved: Self): Research Grant or Support Greer A. Burkholder, MD, MSPH, Eli Lilly (Grant/Research Support) Sarah Kattakuzhy, MD, Gilead Sciences (Scientific Research Study Investigator, Research Grant or Support) Elana S. Rosenthal, MD, Gilead Sciences (Research Grant or Support)Merck (Research Grant or Support)

scholarly journals 113. Reliability of Nasopharyngeal PCR for the Detection of Otopathogens in Children with Uncomplicated Acute Otitis Media

2021 ◽  
Vol 8 (Supplement_1) ◽  
pp. S69-S70
Author(s):  
Holly M Frost ◽  
Thresia Sebastian ◽  
Amy Keith ◽  
Melanie Kurtz ◽  
Andreas Bress ◽  
...  
Keyword(s):  
Negative Predictive Value ◽  
Otitis Media ◽  
Predictive Value ◽  
San Diego ◽  
Clinical Care ◽  
Acute Otitis Media ◽  
Nucleic Acid Amplification ◽  
Research Support ◽  
Sensitivity Specificity ◽  
Research Grant

Abstract Background Among children with acute otitis media (AOM) S.pneumoniae, H.influenzae, and M.catarrhalis are the predominant bacterial otopathogens. There is a high correlation between nasopharyngeal (NP) and middle ear fluid (MEF) organisms during AOM. Thus, NP samples could serve as a surrogate for detection of otopathogens and are more easily collected in a typical practice environment than MEF. Though culture is considered the gold standard for detection, it is time-consuming, which can limit its diagnostic utility to guide clinical care. We aimed to determine the sensitivity, specificity, positive (PPV) and negative predictive value (NPV) for NP qualitative PCR for bacterial otopathogens compared to NP culture. Methods Patients age 6-35 months with uncomplicated AOM who were prospectively enrolled in an AOM study in Denver, CO from Jan 2019-Dec 2020 were included. All patients had an NP flocked swab (Eswab®, Copan Diagnostics) at enrollment. Otopathogen culture was completed using standard techniques. Nucleic acids were extracted using the NucliSENS® easyMAG® system (Quidel, San Diego, CA) per manufacturer’s instructions. Multiplex RT-PCR for S.pneumoniae, H.influenzae, and M.catarrhalis was completed using Lyra® (Quidel, San Diego, CA) and AnDiaTec® assay kits (Quidel Germany GmbH, Kornwestheim, Germany). Nucleic acid amplification and detection was completed on the Applied Biosystems® (ABI) 7500 Fast Dx Real-Time PCR Instrument. Results Of the 80 children included, 18 (22.5%) had no organism detected on culture, 31 (38.8%) had one and 31 (38.8%) had multiple organisms detected. The most commonly identified organisms on culture were M.catarrhalis (42, 52.5%), followed by S.pneumoniae (30, 37.5%), and H.influenzae (17, 21.3%). Of H.influenzae isolates 8 (47.1%) produced beta-lactamase. The sensitivity of PCR was high ( >94%) for all organisms whereas the specificity was lower (50.0-77.8%) and varied by organism (Table). NPV were high ( >96%) for all otopathogens, whereas, PPV ranged from 53.3 to 68.9%. PCR detected 1.6 times more organisms than culture (149 vs. 96). Sensitivity, specificity, positive and negative predictive value of PCR compared to culture for otopathogens. Conclusion NP PCR has a high predictive value for excluding otopathogens and warrants further exploration as a diagnostic tool to evaluate for otopathogens in children. Disclosures Andreas Bress, PhD, Quidel Laboratories- Germany (Employee) Richard Egan, PhD, Quidel Laboratories (Employee) Samuel R. Dominguez, MD, PhD, BioFire Diagnostics (Consultant, Research Grant or Support)DiaSorin Molecular (Consultant)Pfizer (Grant/Research Support) Samuel R. Dominguez, MD, PhD, BioFire (Individual(s) Involved: Self): Consultant, Research Grant or Support; DiaSorin Molecular (Individual(s) Involved: Self): Consultant; Pfizer (Individual(s) Involved: Self): Grant/Research Support

scholarly journals 929. Characteristics Associated with Pain in Older People Living with HIV

2020 ◽  
Vol 7 (Supplement_1) ◽  
pp. S498-S498
Author(s):  
Maile Karris ◽  
Peter Mazonson ◽  
Theoren Loo ◽  
Jeff Berko ◽  
Frank Spinelli ◽  
...  
Keyword(s):  
Older People ◽  
Low Income ◽  
Well Being ◽  
People Living With Hiv ◽  
Research Support ◽  
Patient Reported ◽  
The Us ◽  
Chronic Pain Conditions ◽  
Living With Hiv ◽  
Anxiety Depression

Abstract Background Pain impacts up to 55% of people living with HIV (PLWH) and negatively impacts function. To date, limited data exist regarding factors that contribute to pain in older PLWH. Methods Data were utilized from the Aging with Dignity, Health, Optimism and Community (ADHOC) cohort, an observational study of older PLWH from ten clinics across the U.S. that collects patient-reported outcomes (PROs) on socioeconomic, psychosocial, and health factors. To measure pain, ADHOC participants were asked whether they had been diagnosed with back pain, hip pain, joint pain, or muscle pain, and were also instructed to report chronic pain conditions that were not listed. Bivariate analyses were performed to determine the associations between pain and PROs. Results Of 1,051 participants, 66% reported at least one type of pain. Factors associated with pain included multimorbidity, low income, anxiety, loneliness, depression, tobacco use, and older age (Table 1). Factors negatively associated with pain included employment, higher cognitive function, higher quality of life, greater resilience, higher social well-being, and alcohol use. Table 1. Characteristics associated with pain among older people living with HIV. Pairwise correlations are reported above using correlation coefficient r. Conclusion Improving pain management is currently a priority in the US healthcare system. Some factors identified in this study, including systemic issues such as socioeconomic status and employment, are not easily modifiable. Other factors, such as anxiety, depression, and smoking, are modifiable and therefore represent targets for interventions focused on improving pain and its sequelae in older PLWH. Disclosures Maile Karris, MD, Gilead Sciences (Grant/Research Support)Viiv Healthcare (Grant/Research Support) Peter Mazonson, MD, MBA, ViiV Healthcare (Grant/Research Support) Theoren Loo, MS, BS, ViiV Healthcare (Grant/Research Support) Jeff Berko, MPH, BS, ViiV Healthcare (Grant/Research Support) Frank Spinelli, MD, ViiV Healthcare (Employee) Andrew Zolopa, MD, ViiV Healthcare (Employee)

SAT0049 DIFFERENCES BETWEEN EARLY AND ESTABLISHED RHEUMATOID ARTHRITIS IN TIME TO ACHIEVING CDAI BUT NOT FATIGUE LOW DISEASE ACTIVITY AND REMISSION: DATA FROM THE OBRI REGISTRY

2020 ◽  
Vol 79 (Suppl 1) ◽  
pp. 955-956
Author(s):  
J. Pope ◽  
M. Movahedi ◽  
E. Rampakakis ◽  
A. Cesta ◽  
J. Sampalis ◽  
...  
Keyword(s):  
Rheumatoid Arthritis ◽  
Disease Activity ◽  
Clinical Care ◽  
Disease State ◽  
Practice Research ◽  
Research Support ◽  
Low Disease Activity ◽  
Early Ra ◽  
Research Initiative ◽  
Patient Reported

Background:Previous studies have shown that early diagnosis and treatment of rheumatoid arthritis (RA) is important for achieving comprehensive disease control and have identified established disease as an independent predictor of worse clinical outcomes. However, it is not clear whether these differences are driven by patient-reported or objective outcome measures.Objectives:The aim of this analysis was to compare the time to achieving low disease activity (LDA) and remission based on both objective and patient-reported outcomes in people with early vs. established RA followed in routine clinical care.Methods:RA patients enrolled in the Ontario Best Practices Research Initiative (OBRI) registry that were not in a low disease state at baseline based on the CDAI, SJC28, PtGA, pain and fatigue criteria below, and had at least six months of follow-up, were included in the analysis. LDA was defined as CDAI≤10, SJC28≤2, TJC28≤2, PtGA≤2cm, pain≤2cm, fatigue≤2cm, and MDGA≤2cm; remission was defined as CDAI≤2.8, SJC28≤1, TJC28≤1, PtGA≤1cm, pain≤1cm, fatigue≤1cm, and MDGA≤1cm. Between group (early vs. established) differences in time to first LDA/remission were assessed with Kaplan-Meier survival analysis and the log-rank test.Results:A total of 986 patients were included, 347 (35%) with early RA and 639 (65%) with established RA. At baseline, patients with early RA were significantly younger (55.8 vs. 58.3 years) and were less likely to have a comorbidity (94.5% vs. 97.5%) or an erosion (26.7% vs. 62.6%), be RF-positive (65.6% vs. 74.2%), use bDMARDs (7.5% vs. 26.6%), and be non-smokers (38.9% vs. 47.3%).Time to achieving LDA based on CDAI (HR [95%CI]: (1.23 [1.07,1.43]), SJC28 (1.32 [1.15,1.51]), TJC28 (1.18 [1.02,1.36]), MDGA (1.28 [1.10,1.49]), PtGA (1.23 [1.05,1.44]), and pain (1.29 [1.09,1.52]) were significantly shorter in early RA compared to established RA. Similarly, time to achieving remission based on CDAI (HR [95%CI]: (1.50 [1.22,1.84]), SJC28 (1.35 [1.17,1.55]), MDGA (1.25 [1.06,1.47]), PtGA (1.22 [1.02,1.47]), and pain (1.37 [1.14,1.65]) were significantly shorter in early RA. However, no differences were observed in time to remission based on TJC28 (1.12 [0.96,1.31]) and either LDA or remission based on fatigue (LDA (1.10 [0.94,1.30]); remission (1.09 [0.92,1.31]).Adjustment for age, gender, presence of comorbidities, and baseline scores did not alter the results.Conclusion:Time to achieving low disease state or remission based on various objective and patient-reported measures is significantly shorter in early compared to established RA with the exception of fatigue.Disclosure of Interests:Janet Pope Grant/research support from: AbbVie, Bristol-Myers Squibb, Eli Lilly & Company, Merck, Roche, Seattle Genetics, UCB, Consultant of: AbbVie, Actelion, Amgen, Bayer, Boehringer Ingelheim, Bristol-Myers Squibb, Eicos Sciences, Eli Lilly & Company, Emerald, Gilead Sciences, Inc., Janssen, Merck, Novartis, Pfizer, Roche, Sandoz, Sanofi, UCB, Speakers bureau: UCB, Mohammad Movahedi Consultant of: Allergan, Emmanouil Rampakakis: None declared, Angela Cesta: None declared, John Sampalis: None declared, Claire Bombardier Grant/research support from: Dr Bombardier reports sources of funding for Ontario Best Practice Research Initiative Research grants from Abbvie, Janssen, Amgen, Medexus, Merck, Pfizer, and Novartis outside of the submitted work. Consulting Agreements: Abbvie, Covance, Janssen, Merck, Pfizer, Sanofi and Novartis outside of the submitted work. Advisory Board Membership: Hospira, Sandoz, Merck, Pfizer and Novartis outside of the submitted work.

scholarly journals Use of geosocial networking applications is independently associated with diagnosis of STI among men who have sex with men testing for STIs: findings from the cross-sectional MSM Internet Survey Ireland (MISI) 2015

2018 ◽  
Vol 95 (4) ◽  
pp. 279-284 ◽  
Author(s):  
Lois O’Connor ◽  
Kate O'Donnell ◽  
Peter Barrett ◽  
Ford Colin Ian Hickson ◽  
Daniel McCartney ◽  
...  
Keyword(s):  
Sexual Partner ◽  
Total Population ◽  
Sexual Partners ◽  
Internet Survey ◽  
Sexually Active ◽  
Cross Sectional ◽  
Sexual Behaviours ◽  
Number Of Sexual Partners ◽  
Study Population ◽  
Sex With Men

ObjectivesMSM Internet Survey Ireland (MISI) 2015 was an anonymous, self-completed, cross-sectional internet survey assessing sexual behaviours and health needs among men who have sex with men (MSM) in Ireland. We explored factors associated with self-reported STI diagnosis among MSM who were sexually active and had an STI test in the previous year.MethodsWe compared the study population (n=1158; 37% of total population), with the sexually active MISI population not testing for STIs (n=1620; 52% of total population). Within the study population, we identified sociodemographics and sexual behaviours associated with self-reporting STI diagnosis. We used multivariable logistic regression to estimate adjusted odds ratios (aORs).ResultsThe sociodemographics, lifestyle and sexual behaviours of the study population differed significantly from the sexually active MISI population who did not test for STIs. Within the study population, 65% met a sexual partner via geosocial networking smartphone application (GSNa) and 21% self-reported an STI diagnosis in the previous year. On univariable analysis, factors associated with STI diagnosis included: older age, identifying as gay, HIV-positive status, increasing number of sexual partners in the previous year, condomless anal intercourse (CAI) with ≥2 non-steady partners and using GSNa to meet a new sexual partner in the previous year or most recent sexual partner. On multivariable analysis, STI diagnosis was associated with: being aged 25–39 years (aOR 1.8, 95% CI 1.04 to 3.15), CAI with ≥2 non-steady partners (aOR 2.8, 95% CI 1.84 to 4.34), total number of sexual partners (aOR 1.02, 95% CI 1.00 to 1.03) and using GSNa to meet a new sexual partner (aOR 1.95, 95% CI 1.12 to 3.39).ConclusionsSTI diagnosis among MSM testing for STIs is associated with GSNa use, as well as sexual behaviours. GSNas are key settings for STI prevention interventions, which should prioritise men with high numbers of sexual partners and those with multiple CAI partners.

scholarly journals Efficacy and Safety of Tenofovir Alafenamide vs. Tenofovir Disoproxil Fumarate in HIV-infected, Virologically Suppressed Black and Non-Blacks Adults Through Week 96: Subgroup Analysis of a Randomized Switch Study

2017 ◽  
Vol 4 (suppl_1) ◽  
pp. S427-S428 ◽  
Author(s):  
Jason A Flamm ◽  
Thanes Vanig ◽  
Joseph Gathe ◽  
Clifford Kinder ◽  
Michael Para ◽  
...  
Keyword(s):  
Subgroup Analysis ◽  
Tenofovir Disoproxil Fumarate ◽  
Study Drug ◽  
Baseline Viral Load ◽  
Controlled Study ◽  
Research Support ◽  
Independent Contractor ◽  
Black Adults ◽  
Tenofovir Alafenamide ◽  
Research Grant

Abstract Background Black adults are disproportionately affected by HIV. Methods We conducted a 96-week subgroup analysis by race (Black vs. non-Black) for efficacy (pre-specified) and safety (post-hoc) from a randomized, double blind, active-controlled study in virologically suppressed HIV-infected individuals who switched to emtricitabine/tenofovir alafenamide (FTC/TAF) from FTC/tenofovir disoproxil fumarate (FTC/TDF) vs. continuing FTC/TDF while remaining on the same third agent. Results Of 663 treated patients, 136 (20.5%) self-identified as Black (FTC /TAF 
n = 69, FTC /TDF n = 67). Baseline viral load, CD4 counts, renal laboratory parameters, and bone mineral density (BMD) were similar between the two arms within Blacks and non-Blacks. For Blacks, virologic success by FDA snapshot algorithm at week 96: FTC /TAF 87.0% vs. FTC /TDF 88.1%; for non-Blacks 89.0% vs. 89.7%. Few participants discontinued study drug due to adverse events in either subgroups (FTC/TAF vs. FTC/TDF: Black 0 vs.. 1.5%; non-Black, 3.0% vs. 1.1%). In assessment of renal and bone safety using estimated glomerular filtration rate (eGFR), renal biomarkers, and BMD, there were differences between two arms that generally favored FTC/TAF over FTC/TDF (Table). In the overall population, no cases of Fanconi syndrome or proximal renal tubulopathy occurred with FTC/TAF; one FTC/TDF participant discontinued study drug due to proximal tubulopathy. Conclusion In virologically suppressed Black adults, FTC/TAF demonstrated improvements in renal and bone safety over FTC/TDF with similar sustained efficacy at week 96. These results support switching to FTC/TAF from FTC/TDF for the treatment of HIV-1 infection in Black adults. Disclosures J. A. Flamm, Gilead: Investigator, Research support; T. Vanig, Gilead: Consultant, Investigator and Speaker’s Bureau, Consulting fee, Research support and Speaker honorarium; J. Gathe, Gilead: Investigator, Research support; C. Kinder, Gilead: Investigator, Research support; M. Para, Gilead: Investigator, Research grant and Research support; B. Rashbaum, Gilead: Investigator and Shareholder, Research support and Speaker honorarium; S. Segal-Maurer, Gilead Sciences: Consultant, Investigator, Scientific Advisor and Speaker’s Bureau, Consulting fee, Research support and Speaker honorarium; Janssen Therapeutics: Speaker’s Bureau, Speaker honorarium; D. Shamblaw, Gilead: Investigator, Research support; M. Wohlfeiler, Gilead: Investigator, Research support; B. Young, Gilead Sciences: Independent Contractor, Investigator, Research Contractor and Scientific Advisor, Consulting fee, Research support and Speaker honorarium; Merck & Co: Scientific Advisor and Speaker’s Bureau, Consulting fee, Research support and Speaker honorarium; ViiV Healthcare: Scientific Advisor, Research grant; C. Zurawski, Gilead: Investigator, Research grant; M. S. Rhee, Gilead: Employee and Shareholder, Salary

scholarly journals Individual and Social Predictors of HIV Status Disclosure in HIV-Positive Individuals in Ahvaz, Khuzestan, Southwest of Iran

2020 ◽  
Vol 9 (2) ◽  
Author(s):  
Shirin Hasanpour ◽  
Mansoureh Fakhouri ◽  
Mojgan Mirghafourvand
Keyword(s):  
High Risk ◽  
Sexual Partner ◽  
Sexual Partners ◽  
Hiv Disclosure ◽  
Hiv Status ◽  
High Risk Behaviors ◽  
Number Of Sexual Partners ◽  
History Of ◽  
Hiv Status Disclosure ◽  
Status Disclosure

Background: Encouraging people who live with HIV (PWLH) to inform their sexual partner about HIV infection is an effective way to reduce the spread of HIV. It reduces the probability of HIV transmission by avoiding high-risk behaviors. Objectives: To determine the predictors of disclosure of HIV status to a sexual partner(s) in PWLH in Khuzestan province, Iran. Patients and Methods: The current descriptive, analytical, cross-sectional study was performed on 89 men and 31 women with HIV/AIDS. Data were collected from October 2016 to February 2017. A convenience sampling method was used to recruit participants. Socio-demographic and Kalichman HIV status disclosure questionnaires were used to collect data. The questionnaire was filled by participants. In addition to socio-demographic information, high-risk sexual behaviors, history of drug and alcohol use, number of sexual partners, and HIV status of the partner were also reported by participants. A multivariate linear regression model with a backward strategy was used to determine the predictors of HIV disclosure. Results: Half of the participants (49.1%) had two or more sexual partners. 46.7% of participants reported that the HIV status of sexual partners is unknown. Frequency of unprotected vaginal, anal, and oral relationship were 87.5%, 43.3%, and 58.5%, respectively. 71.7% of participants had a history of drug abuse, and 43.3% were current substance users. More than half (58.3%) had a history of imprisonment. Based on the multivariate linear regression model, the variables of employment status, HIV status of sexual partner, unprotected vaginal sex, unprotected anal sex, and recurrent consumption of narcotic drugs were predictors of HIV disclosure. These variables explained 58.7% of the variance in the total score of HIV disclosure. Conclusions: The present study highlighted the need for behavioral interventions, such as providing support and counseling with sexual partners of HIV patients about HIV preventive behaviors, such as condom use, reducing the number of sexual partners, and creation of a positive attitude towards the lives of HIV-positive intravenous drug users to overcome the barriers to reduce high-risk behaviors and drug abuse, through behavioral disease counseling centers.

Sign in / Sign up

Export Citation Format

Share Document